kneat.com (KSI) AI Stock Analysis

• Market Cap: C$537.81M
• Dividend Yield: N/A
• Average Volume (3M): 156.17K
• Price to Earnings (P/E): 1048.1
• Beta (1Y): 0.98
• Revenue Growth: 39.32%
• EPS Growth: N/A
• Country: CA
• Employees: 297
• Sector: Healthcare
• Sector Strength: 47
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 0.00
• Shares Outstanding: 95,018,974
• 10 Day Avg. Volume: 133,852
• 30 Day Avg. Volume: 156,168
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$7.00
• Price Target Upside: 23.67% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 48 Neutral
• Price Target: C$5.50 ▼(-2.83% Downside)

The overall stock score is primarily influenced by financial performance and technical analysis. While the company shows strong revenue growth and a solid gross profit margin, profitability challenges and negative free cash flow weigh heavily on the score. The technical indicators suggest a bearish trend, further impacting the score. The extremely high P/E ratio indicates overvaluation, which is a significant concern. Despite positive insights from the earnings call, the financial and technical weaknesses dominate the overall assessment.

kneat.com Business Overview & Revenue Model

Company Description

kneat.com, inc. designs, develops, and supplies software for data and document management within regulated environments in the United States, Ireland, Canada, and internationally. The company offers Kneat Gx platform, a configurable commercial off-the-shelf application focused on validation lifecycle management and testing for biotechnology, pharmaceutical, and medical device manufacturing industries. Its platform is used in process, computer system, cleaning, analytical instrument, method, utility and facility, equipment, and cold chain validation, as well commissioning and qualification, and electronic logbook management. The company also provides software-related services, including training, installation, upgradation, consulting, and maintenance, as well as process mapping, project management, and other services. kneat.com, inc. is headquartered in Limerick, Ireland.

How the Company Makes Money

Kneat.com generates revenue primarily through subscription fees for its cloud-based software platform. The company employs a Software-as-a-Service (SaaS) model, where clients subscribe to its services on a recurring basis. Additionally, Kneat.com may earn income through professional services, including implementation support, training, and consulting. Partnerships with life sciences companies and strategic collaborations further enhance its revenue potential by expanding its market reach and customer base.

kneat.com Financial Statement Overview

Summary

kneat.com shows strong revenue growth and a solid balance sheet, but ongoing losses and negative margins due to high expenses are concerning. Cash flow management is improving, but free cash flow remains negative.

Income Statement

kneat.com has demonstrated consistent revenue growth over recent years, with a notable increase of 8.14% in the TTM period compared to the previous year. However, the company is struggling with profitability, as evidenced by its negative EBIT and net profit margins, indicating that expenses are significantly impacting the bottom line.

Balance Sheet

The balance sheet reflects a solid equity position with a debt-to-equity ratio of 0.37, indicating moderate leverage and financial stability. The equity ratio is relatively strong at 48.9%, suggesting that the company is well-capitalized. However, the company must manage its liabilities effectively to maintain this balance.

Cash Flow

Cash flow analysis reveals positive operating cash flow, which is a good indicator of internal cash generation. However, free cash flow remains negative, highlighting challenges in covering capital expenditures. The company shows improvement in cash flow management, but further efficiency is necessary to enhance free cash flow.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	56.65M	48.94M	34.22M	23.75M	15.50M	7.42M
Gross Profit	42.68M	36.76M	23.13M	14.65M	9.32M	2.88M
EBITDA	16.02M	6.27M	-5.77M	-3.20M	-5.11M	-2.30M
Net Income	476.72K	-7.73M	-14.12M	-9.15M	-9.86M	-5.88M
Balance Sheet
Total Assets	134.67M	124.58M	64.50M	50.41M	51.28M	33.80M
Cash, Cash Equivalents and Short-Term Investments	66.77M	58.89M	15.25M	12.28M	21.56M	8.66M
Total Debt	30.66M	29.26M	28.17M	7.09M	7.86M	9.52M
Total Liabilities	68.29M	59.51M	49.73M	24.43M	17.09M	14.59M
Stockholders Equity	66.38M	65.07M	14.76M	25.98M	34.19M	19.21M
Cash Flow
Free Cash Flow	-5.54M	-10.09M	-18.39M	-9.82M	-7.74M	-9.28M
Operating Cash Flow	15.31M	9.79M	-1.28M	2.99M	2.31M	-1.98M
Investing Cash Flow	-18.94M	-17.52M	-15.97M	-11.91M	-10.04M	-6.43M
Financing Cash Flow	30.23M	50.62M	20.27M	-383.91K	21.20M	13.11M

kneat.com Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 5.66
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:KSI, the sentiment is Neutral. The current price of 5.66 is below the 20-day moving average (MA) of 5.69, below the 50-day MA of 5.88, and below the 200-day MA of 6.09, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 48.08 is Neutral, neither overbought nor oversold. The STOCH value of 24.62 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:KSI.

kneat.com Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
VHI	65 Neutral	C$838.18M	149.73	3.23%	―	41.68%	-16.15%
AIML	55 Neutral	C$8.67M	―	-244.35%	―	-71.31%	-53.11%
ADK	52 Neutral	C$26.48M	―	366.78%	―	-47.10%	-19.32%
Sector *	51 Neutral	$7.88B	-0.12	-39.86%	2.18%	21.38%	-1.56%
KSI	48 Neutral	C$537.81M	1,048.15	0.99%	―	39.32%	―
TREIF	―	$32.75M	―	-507.20%	―	―	―
UDOCF	―	$12.68M	―	-9999.00%	―	―	―

kneat.com Corporate Events

Kneat Secures Major Agreement with Global Medical Tech Leader

Kneat.com has secured a three-year Master Services Agreement with a major global medical technology company, a division of a larger Asian manufacturer. This agreement will see the implementation of Kneat’s Gx platform for equipment validation, further solidifying Kneat’s position in the life sciences sector. The adoption by large-scale life sciences companies highlights Kneat’s technical capabilities and the strategic trust placed in their platform.

The most recent analyst rating on (TSE:KSI) stock is a Buy with a C$4.90 price target. To see the full list of analyst forecasts on kneat.com stock, see the TSE:KSI Stock Forecast page.

Kneat.com Reports Record Q2 2025 Revenue and Strategic Growth

Kneat.com announced a record revenue of $15.4 million for the second quarter of 2025, marking a 32% increase from the previous year. The company’s gross margin reached 75%, and its annual recurring revenue grew by 43% to $64.8 million. These financial results highlight Kneat’s strong market position and the growing adoption of its Kneat Gx platform. The company has also expanded its executive leadership team and secured significant agreements with multinational companies, further solidifying its presence in the industry.

The most recent analyst rating on (TSE:KSI) stock is a Buy with a C$4.90 price target. To see the full list of analyst forecasts on kneat.com stock, see the TSE:KSI Stock Forecast page.

Kneat to Release Q2 2025 Financial Results

Kneat.com announced it will release its second-quarter financial results for 2025 on August 5, after the TSX market closes. The announcement will be followed by a conference call with key executives on August 6, aimed at providing insights to sell-side analysts. This release is significant for stakeholders as it reflects Kneat’s ongoing commitment to transparency and could impact its market positioning.

The most recent analyst rating on (TSE:KSI) stock is a Buy with a C$4.90 price target. To see the full list of analyst forecasts on kneat.com stock, see the TSE:KSI Stock Forecast page.

Kneat Announces Leadership Change with New CFO Appointment

Kneat.com has announced a change in its senior leadership with the retirement of CFO Hugh Kavanagh, who has significantly contributed to the company’s growth. Dave O’Reilly, with a strong background in scaling businesses and financial strategy, will take over as CFO, potentially impacting Kneat’s operations and market positioning positively as the company continues to scale in the Life Sciences sector.

The most recent analyst rating on (TSE:KSI) stock is a Buy with a C$4.90 price target. To see the full list of analyst forecasts on kneat.com stock, see the TSE:KSI Stock Forecast page.

Kneat Secures Major Agreement with Global Healthcare Leader

Kneat.com has announced a multi-year Master Services Agreement with a major healthcare technology and diagnostics company to digitize its validation processes using the Kneat Gx platform. This partnership highlights the growing trend of digital validation in the life sciences industry, as evidenced by the increasing percentage of organizations adopting such technologies. The agreement is expected to enhance efficiency, quality, and compliance for the healthcare company, reinforcing Kneat’s position as a leader in digital validation solutions.

The most recent analyst rating on (TSE:KSI) stock is a Buy with a C$4.90 price target. To see the full list of analyst forecasts on kneat.com stock, see the TSE:KSI Stock Forecast page.

Kneat.com Confirms Board Elections and Auditor Re-Appointment at 2025 AGM

Kneat.com announced the results of its 2025 Annual General Meeting, where all director nominees were elected to the board, and KPMG LLP was re-appointed as auditors. This reaffirms the company’s stable governance and commitment to maintaining high standards in its operations, potentially enhancing stakeholder confidence and industry positioning.

The most recent analyst rating on (TSE:KSI) stock is a Buy with a C$4.90 price target. To see the full list of analyst forecasts on kneat.com stock, see the TSE:KSI Stock Forecast page.

Kneat Secures Major Agreement with Global Diagnostics Leader

Kneat.com has announced a significant three-year Master Services Agreement with a major U.S.-based manufacturer of clinical diagnostics, which operates globally. This agreement will see the diagnostics company initially use Kneat’s digital platform, Kneat Gx, to digitize its equipment validation process, reflecting a broader industry trend towards digitalization for improved quality and compliance. This partnership underscores Kneat’s market position as a leader in digital validation solutions, promising enhanced efficiency and compliance benefits for its clients.

The most recent analyst rating on (TSE:KSI) stock is a Buy with a C$4.90 price target. To see the full list of analyst forecasts on kneat.com stock, see the TSE:KSI Stock Forecast page.